103 research outputs found

    Design of a Cooper pair box electrometer for application to solid-state and astroparticle physics

    Get PDF
    We describe the design and principle of operation of a fast and sensitive electrometer operated at millikelvin temperatures, which aims at replacing conventional semiconducting charge amplifiers in experiments needing low back-action or high sensitivity. The electrometer consists of a Cooper Pair box (CPB) coupled to a microwave resonator, which converts charge variations to resonance frequency shifts. We analyze the dependence of the sensitivity on the various parameters of the device, and derive their optimization. By exploiting the nonlinearities of this electrometer, and using conventional nanofabrication and measurement techniques, a charge sensitivity of a few 107e/Hz10^{- 7} e / \sqrt{Hz} can be achieved which outperforms existing single charge electrometers.Comment: 13 pages, 7 figure

    Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

    Get PDF
    Background: Human immunodeficiency virus (HIV) infection that persists despite antiretroviral therapy (ART) is a daunting problem. Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART. Methods: Patients with plasma HIV RNA,50 c/mL added sustained-release VPA (Depakote ERH) twice daily, RAL 400 mg twice daily, or ENF 90 mcg twice daily. Change in RCI was measured by outgrowth assays. Low-level viremia was quantitated by single-copy plasma HIV RNA assay (SCA). Results: In three patients on standard ART a depletion of RCI was observed after 16 weeks of VPA, but this effect waned over up to 96 weeks of further VPA. In two patients ENF added to stable ART had no effect on RCI. Simultaneous intensification with ENF and addition of VPA had no effect on RCI frequency in one patient, and resulted in a 46% decline in a second. No significant depletion of RCI (.50%) was seen in six volunteers after the addition of RAL and VPA. In 4 of the 6 patients this lack of effect might be attributed to intermittent viremia, low VPA levels, or intermittent study therapy adherence. Overall, there was no effect of the addition of RAL or ENF on low-level viremia measured by SCA. Conclusions: The prospective addition of VPA and RAL, VPA and ENF, or ENF failed to progressively reduce the frequency of RCI, or ablate intermittent and low-level viremia. New approaches such as more potent HDAC inhibition, alone or in combination with intensified ART or other agents that may disrupt proviral latency must be pursued

    Erfassung von Wissensorganisationssystemen in BARTOC - Ergebnis eines Projektseminars an der Hochschule Hannover

    Get PDF
    Das Basel Register of Thesauri, Ontologies & Classifications (BARTOC) hat sich innerhalb weniger Jahre mit mehr als 2.700 Einträgen zu einem umfangreichen Verzeichnis von Wissensorganisationssystemen entwickelt. Im Sommersemester 2017 wurde diese Entwicklung von einem Projektseminar mit Bachelor-Studierenden der Hochschule Hannover begleitet. Eine Revision und Erweiterung der Inhalte von BARTOC führte zu einer besseren Abdeckung ausgewählter Metadatenfelder. Darüber hinaus wurden verschiedene Statistiken, Informationsmaterialien und ein neues Logo erstellt

    ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

    Get PDF
    Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1 infection. We therefore investigated the level of plasma HIV-1 RNA in patients with viremia suppressed to less than 50–75 copies/ml on standard protease inhibitor- or non-nucleoside reverse transcriptase inhibitor-containing antiretroviral therapy using a new, real-time PCR-based assay for HIV-1 RNA with a limit of detection of one copy of HIV-1 RNA. Single copy assay results revealed that >80% of patients on initial antiretroviral therapy for 60 wk had persistent viremia of one copy/ml or more with an overall median of 3.1 copies/ml. The level of viremia correlated with pretherapy plasma HIV-1 RNA but not with the specific treatment regimen. Longitudinal studies revealed no significant decline in the level of viremia between 60 and 110 wk of suppressive antiretroviral therapy. These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy

    The occurrence of tarsal injuries in male mice of C57BL/6N substrains in multiple international mouse facilities.

    Get PDF
    Dislocation in hindlimb tarsals are being observed at a low, but persistent frequency in group-housed adult male mice from C57BL/6N substrains. Clinical signs included a sudden onset of mild to severe unilateral or bilateral tarsal abduction, swelling, abnormal hindlimb morphology and lameness. Contraction of digits and gait abnormalities were noted in multiple cases. Radiographical and histological examination revealed caudal dislocation of the calcaneus and partial dislocation of the calcaneoquartal (calcaneus-tarsal bone IV) joint. The detection, frequency, and cause of this pathology in five large mouse production and phenotyping centres (MRC Harwell, UK; The Jackson Laboratory, USA; The Centre for Phenogenomics, Canada; German Mouse Clinic, Germany; Baylor College of Medicine, USA) are discussed

    Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

    Get PDF
    Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy
    corecore